Description
EXERCISE 3RD OPTION YEAR FOR ATROPINE/DIPHENOXYLATE HCL TABLETS, EFFECTIVE MAY 27, 2026 THROUGH MAY 26, 2027 WITH NO PRICE CHANGES
Base award description: NEW AWARD FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC . PERIOD OF PERFORMANCE IS MAY 27, 2023 THROUGH MAY 26, 2024 WITH FOUR ONE YEAR OPTION YEARS.
Modification chain · 10 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-02-08+$0= $0
- Mod P000012023-04-14+$0= $0
- Mod P000022024-02-09+$0= $0
- Mod P000032024-02-13+$0= $0
- Mod P000042024-04-10+$0= $0
- Mod P000052025-01-15+$0= $0
- Mod P000062025-01-30+$0= $0
- Mod P000072025-04-08+$0= $0
- Mod P000082025-12-31+$0= $0
- Mod P000092026-04-01+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-02-08 | +$0 | $0 | NEW AWARD FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC . PERIOD OF PERFORMANCE IS MAY 27, 2023 THR… |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2023-04-14 | +$0 | $0 | INCORPORATE DSCSA FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 5/15/2023. |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2024-02-09 | +$0 | $0 | COST RECOVERY FEE AND SUBMISSION OF QUARTERLY SALES REPORT FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX,… |
| Mod P00003· ADD SUBCONTRACTING PLAN | 2024-02-13 | +$0 | $0 | 2024 SUBCONTRACTING PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 1/1/2024-12/31/2024 |
| Mod P00004· EXERCISE AN OPTION | 2024-04-10 | +$0 | $0 | EXERCISE OPTION YEAR ONE FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 5/27/2024 THROUGH 5… |
| Mod P00005· ADD SUBCONTRACTING PLAN | 2025-01-15 | +$0 | $0 | 2025 SUBCONTRACTIN PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 1/1/2025 THROUGH 12/… |
| Mod P00006· ADD SUBCONTRACTING PLAN | 2025-01-30 | +$0 | $0 | REVISED 2025 SUBCONTRACTIN PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 1/1/2025 THR… |
| Mod P00007· EXERCISE AN OPTION | 2025-04-08 | +$0 | $0 | EXERCISE OPTION YEAR 2 FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE MAY 27, 2025 THROUGH… |
| Mod P00008· ADD SUBCONTRACTING PLAN | 2025-12-31 | +$0 | $0 | INCORPORATE SPECGX 2026 SUBCONTRACTING PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE… |
| Mod P00009· EXERCISE AN OPTION | 2026-04-01 | +$0 | $0 | EXERCISE 3RD OPTION YEAR FOR ATROPINE/DIPHENOXYLATE HCL TABLETS, EFFECTIVE MAY 27, 2026 THROUGH MAY 26, 2027 W… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI SJ9MSB1UXGL8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24526N0786 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $4,435 | FY2026 |
| 36C24526N0382 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $5,213 | FY2026 |
| 36C24525N0842 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $5,572 | FY2025 |
| 36C24525N0365 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $5,328 | FY2025 |
| 36C24524N0852 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $4,639 | FY2024 |
| 36C24524N0407 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $4,884 | FY2024 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79723D0016_3600 · retrieved 2026-09-26.